{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:32:55Z","timestamp":1793392375391,"version":"4.5.0"},"reference-count":99,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurology International"],"abstract":"<jats:p>Purpose of Review. This is a comprehensive review of the literature regarding the use of Aripiprazole lauroxil for schizophrenia. This review presents the background, evidence, and indications for using aripiprazole lauroxil to treat schizophrenia in the context of current theories on the development of schizophrenia. Recent Findings. Schizophrenia is a chronic mental health disorder that currently affects approximately 3.3 million people in the United States. Its symptoms, which must be present for more than six months, are comprised of disorganized behavior and speech, a diminished capacity to comprehend reality, hearing voices unheard by others, seeing things unseen by others, delusions, decreased social commitment, and decreased motivation. The majority of these symptoms can be managed with antipsychotic medication. Aripiprazole lauroxil is a long-acting intramuscular injection that works as a combination of partial agonist activity at D2 and 5-HT1A receptors combined with antagonist activity at 5-HT2A receptors. It can be dosed as a 4-, 6-, or 8-week injection, depending on oral dosage. Aripiprazole lauroxil was FDA approved in October of 2015. Summary. Schizophrenia is a severe psychiatric disorder if left untreated. There are multiple medications to help treat schizophrenia. One antipsychotic agent, aripiprazole lauroxil, offers long duration injections that optimize and improve compliance. Known side effects include weight gain, akathisia, neuroleptic malignant syndrome, tardive dyskinesia, and orthostatic hypotension. Aripiprazole lauroxil is an FDA-approved drug that can be administered monthly, every six weeks, or every two months and has been shown to be both safe and effective.<\/jats:p>","DOI":"10.3390\/neurolint13030029","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T05:00:10Z","timestamp":1625115610000},"page":"279-296","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review"],"prefix":"10.3390","volume":"13","author":[{"given":"Kunal","family":"Maini","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Louisiana State University Shreveport, Shreveport, LA 71103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley","family":"Gould","sequence":"additional","affiliation":[{"name":"Shreveport School of Medicine, Louisiana State University, Shreveport, LA 71103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Hicks","sequence":"additional","affiliation":[{"name":"Shreveport School of Medicine, Louisiana State University, Shreveport, LA 71103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Iqbal","sequence":"additional","affiliation":[{"name":"Shreveport School of Medicine, Louisiana State University, Shreveport, LA 71103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"James","family":"Patterson","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Louisiana State University Shreveport, Shreveport, LA 71103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber N.","family":"Edinoff","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Louisiana State University Shreveport, Shreveport, LA 71103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7961-3931","authenticated-orcid":false,"given":"Elyse M.","family":"Cornett","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Louisiana State University Shreveport, Shreveport, LA 71103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7224-3322","authenticated-orcid":false,"given":"Adam M.","family":"Kaye","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA 95211, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Viswanath","sequence":"additional","affiliation":[{"name":"College of Medicine-Phoenix, University of Arizona, Phoenix, AZ 85004, USA"},{"name":"Department of Anesthesiology, Creighton University School of Medicine, Omaha, NE 68124, USA"},{"name":"Valley Anesthesiology and Pain Consultants\u2014Envision Physician Services, Phoenix, AZ 85004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3652-6085","authenticated-orcid":false,"given":"Ivan","family":"Urits","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Louisiana State University Shreveport, Shreveport, LA 71103, USA"},{"name":"Beth Israel Deaconess Medical Center, Department of Anesthesiology, Critical Care, and Pain Medicine, Harvard Medical School, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Kaye","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Louisiana State University Shreveport, Shreveport, LA 71103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,1]]},"reference":[{"key":"ref_1","first-page":"1","article-title":"Schizophrenia","volume":"12","author":"Kahn","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/schbul\/sbp094","article-title":"Cognitive impairment in schizophrenia and affective psychoses: Implications for dsm-v criteria and beyond","volume":"36","author":"Bora","year":"2010","journal-title":"Schizophr. Bull."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1001\/jamapsychiatry.2013.155","article-title":"Schizophrenia is a cognitive illness: Time for a change in focus","volume":"7","author":"Kahn","year":"2013","journal-title":"JAMA Psychiatry Am. Med. Assoc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.4088\/JCP.13049tx5c","article-title":"Assessing disability in schizophrenia: Tools and contributors","volume":"75","author":"Harvey","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1016\/j.scog.2014.03.001","article-title":"The course and correlates of everyday functioning in schizophrenia","volume":"1","author":"Reichenberg","year":"2014","journal-title":"Schizophr. Res. Cogn."},{"key":"ref_6","unstructured":"American Psychiatric Publishing (2013). DSM-5\u00ae Handbook of Differential Diagnosis. DSM-5\u00ae Handbook of Differential Diagnosis, American Psychiatric Publishing."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1943-278X.2000.tb01063.x","article-title":"Depression, suicide, and suicide prevention in schizophrenia","volume":"30","author":"Fenton","year":"2000","journal-title":"Suicide Life Threat. Behav."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1176\/appi.ajp.157.9.1379","article-title":"Depression in schizophrenia: Perspective in the era of \u201catypical\u201d antipsychotic agents","volume":"157","author":"Siris","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1001\/jama.1990.03450190043026","article-title":"Comorbidity of Mental Disorders With Alcohol and Other Drug Abuse: Results From the Epidemiologic Catchment Area (ECA) Study","volume":"264","author":"Regier","year":"1990","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_10","unstructured":"AHRQ (2021, June 23). Treatments for Schizophrenia in Adults: A Systematic Review e, Available online: www.ahrq.gov."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/epirev\/mxn001","article-title":"Schizophrenia: A concise overview of incidence, prevalence, and mortality. Epidemiologic Reviews","volume":"30","author":"McGrath","year":"2008","journal-title":"Epidemiol. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0006-3223(99)00289-9","article-title":"Schizophrenia: Genes and environment","volume":"47","author":"Tsuang","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1192\/bjp.112.489.819","article-title":"Psychiatric disorders in foster home reared children of schizophrenic mothers","volume":"112","author":"Heston","year":"1966","journal-title":"Br. J. Psychiatry"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrg2045","article-title":"Environmental epigenomics and disease susceptibility","volume":"8","author":"Jirtle","year":"2007","journal-title":"Nat. Rev. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.neubiorev.2014.06.005","article-title":"Alterations in the serotonin system in schizophrenia: A systematic review and meta-analysis of postmortem and molecular imaging studies","volume":"45","author":"Selvaraj","year":"2014","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fnint.2013.00025","article-title":"Serotonin modulation of cortical neurons and networks","volume":"7","author":"Celada","year":"2013","journal-title":"Front. Integr. Neurosci."},{"key":"ref_17","unstructured":"(2021, June 25). The Cortical Serotonin2a Receptor and The Pathology of Schizophrenia: A Likely Accomplice\u2014Pubmed. Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/12641722\/."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.schres.2006.07.003","article-title":"Cortical serotonin7, 1D and 1F receptors: Effects of schizophrenia, suicide and antipsychotic drug treatment","volume":"88","author":"Dean","year":"2006","journal-title":"Schizophr. Res."},{"key":"ref_19","first-page":"S40","article-title":"Clinical staging: A heuristic model for psychiatry and youth mental health","volume":"187","author":"McGorry","year":"2007","journal-title":"Med. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.schres.2016.04.037","article-title":"Understanding the pathophysiology of schizophrenia: Contributions from the Melbourne Psychiatric Brain Bank","volume":"177","author":"Dean","year":"2016","journal-title":"Schizophr. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0166-2236(98)01361-7","article-title":"Acetylcholine in mind: A neurotransmitter correlate of consciousness? Trends in Neurosciences","volume":"22","author":"Perry","year":"1999","journal-title":"Trends Neurosci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1146\/annurev-neuro-062012-170433","article-title":"Muscarinic signaling in the brain. Annual Review of Neuroscience","volume":"36","author":"Thiele","year":"2013","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/sj.mp.4001199","article-title":"Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia","volume":"7","author":"Dean","year":"2002","journal-title":"Mol. Psychiatry"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/ajmg.b.20020","article-title":"Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia","volume":"119","author":"Mancama","year":"2003","journal-title":"Am. J. Med. Genet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/nn1230","article-title":"Progress in the use of microarray technology to study the neurobiology of disease","volume":"7","author":"Mirnics","year":"2004","journal-title":"Nat. Neurosci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1573400052953547","article-title":"Understanding the Pathology of Schizophrenia: The Impact of High- Throughput Screening of the Genome and Proteome in Postmortem CNS","volume":"1","author":"Dean","year":"2005","journal-title":"Curr. Psychiatry Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.neubiorev.2016.03.017","article-title":"A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis","volume":"65","author":"Davis","year":"2016","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1001\/archpsyc.1987.01800190080012","article-title":"Implications of Normal Brain Development for the Pathogenesis of Schizophrenia","volume":"44","author":"Weinberger","year":"1987","journal-title":"Arch. Gen. Psychiatry."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/bmj.295.6600.681","article-title":"Is schizophrenia a neurodevelopmental disorder?","volume":"295","author":"Murray","year":"1987","journal-title":"Br. Med. J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.neuroscience.2012.04.044","article-title":"Dendritic spine pathology in schizophrenia","volume":"251","author":"Glausier","year":"2013","journal-title":"Neuroscience"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/schbul\/sbn187","article-title":"The neurodevelopmental hypothesis of Schizophrenia, revisited","volume":"35","author":"Fatemi","year":"2009","journal-title":"Schizophr. Bull."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0022-3956(82)90038-3","article-title":"Schizophrenia: Caused by a fault in programmed synaptic elimination during adolescence?","volume":"17","author":"Feinberg","year":"1982","journal-title":"J. Psychiatr. Res."},{"key":"ref_33","first-page":"637","article-title":"Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Archives of General Psychiatry","volume":"57","author":"McGlashan","year":"2000","journal-title":"Am. Med. Assoc."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/neu.1079","article-title":"Dendritic reorganization in pyramidal neurons in medial prefrontal cortex after chronic corticosterone administration","volume":"49","author":"Wellman","year":"2001","journal-title":"J. Neurobiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1146\/annurev.clinpsy.4.022007.141248","article-title":"Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia","volume":"4","author":"Walker","year":"2008","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.psychres.2013.12.016","article-title":"Flattened cortisol awakening response in chronic patients with schizophrenia onset after cannabis exposure","volume":"215","author":"Monteleone","year":"2014","journal-title":"Psychiatry Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1017\/S0033291711002078","article-title":"Cannabis, schizophrenia and other non-affective psychoses: 35 years of follow-up of a population-based cohort","volume":"42","author":"Zammit","year":"2012","journal-title":"Psychol. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.psychres.2013.12.038","article-title":"Cannabis use, gender and age of onset of schizophrenia: Data from the \u00c6SOP study","volume":"215","author":"Donoghue","year":"2014","journal-title":"Psychiatry Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jpsychires.2013.10.018","article-title":"Catechol-O-methyltransferase (COMT) genotype moderates the effects of childhood trauma on cognition and symptoms in schizophrenia","volume":"49","author":"Green","year":"2014","journal-title":"J. Psychiatr. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/eip.12022","article-title":"The history of childhood trauma among individuals with ultra high risk for psychosis is as common as among patients with first-episode schizophrenia","volume":"7","author":"Karadayi","year":"2013","journal-title":"Early Interv. Psychiatry"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/JGP.0b013e318211817e","article-title":"The relationship between trauma and clinical outcome variables among older adults with schizophrenia spectrum disorders","volume":"20","author":"Cohen","year":"2012","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1177\/1363461512464625","article-title":"Association between degrees of social defeat and themes of delusion in patients with schizophrenia from immigrant and ethnic minority backgrounds","volume":"49","author":"Li","year":"2012","journal-title":"Transcult. Psychiatry"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2009.03.005","article-title":"Schizophrenia, \u201cjust the facts\u201d 4. Clinical features and conceptualization. Schizophrenia Research","volume":"110","author":"Tandon","year":"2009","journal-title":"Schizophr. Res."},{"key":"ref_44","first-page":"89","article-title":"Schizophrenia, \u201cjust the facts\u201d: What we know in 2008","volume":"106","author":"Keshavan","year":"2008","journal-title":"Part 3: Neurobiology. Schizophr. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1136\/bmj.280.6207.66","article-title":"Molecular pathology of schizophrenia: More than one disease process?","volume":"280","author":"Crow","year":"1980","journal-title":"Br. Med. J."},{"key":"ref_46","first-page":"84","article-title":"Negative Symptoms in Schizophrenia: Definition and Reliability","volume":"39","author":"Andreasen","year":"1982","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1176\/ajp.145.5.578","article-title":"Deficit and nondeficit forms of schizophrenia: The concept","volume":"145","author":"Carpenter","year":"1988","journal-title":"Am. J. Psychiatry."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/schbul\/sbj053","article-title":"The NIMH-MATRICS consensus statement on negative symptoms","volume":"32","author":"Kirkpatrick","year":"2006","journal-title":"Schizophr. Bull."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/schbul\/sbj055","article-title":"Treatment of schizophrenia negative symptoms: Future prospects","volume":"32","author":"Erhart","year":"2006","journal-title":"Schizophr. Bull."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1600-0447.2006.00947.x","article-title":"Negative symptoms of schizophrenia: A problem that will not go away","volume":"115","author":"Stahl","year":"2007","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1001\/archpsyc.1979.01780120045006","article-title":"Thought, Language, and Communication Disorders: I. Clinical Assessment, Definition of Terms, and Evaluation of Their Reliability","volume":"36","author":"Andreasen","year":"1979","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/0010-440X(88)90062-4","article-title":"Depressive symptoms in schizophrenia: Comprehensive differential diagnosis","volume":"29","author":"Bartels","year":"1988","journal-title":"Compr. Psychiatry"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/oxfordjournals.schbul.a033362","article-title":"Depression during the longitudinal course of schizophrenia","volume":"25","author":"Sands","year":"1999","journal-title":"Schizophr. Bull."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.schres.2006.09.027","article-title":"The burden of depressive symptoms in the long-term treatment of patients with schizophrenia","volume":"90","author":"Conley","year":"2007","journal-title":"Schizophr. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1080\/00048670701579041","article-title":"Meta-analysis of depressive symptoms in dual-diagnosis schizophrenia","volume":"41","author":"Potvin","year":"2007","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1001\/archpsyc.1991.01810310036007","article-title":"Neuropsychological Function in Schizophrenia: Selective Impairment in Memory and Learning","volume":"48","author":"Saykin","year":"1991","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.biopsych.2005.01.003","article-title":"Defining a cognitive function decrement in schizophrenia","volume":"57","author":"Keefe","year":"2005","journal-title":"Biol. Psychiatry."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1176\/ajp.156.9.1358","article-title":"Memory impairment in schizophrenia: A meta-analysis","volume":"156","author":"Aleman","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1192\/bjp.187.6.500","article-title":"Episodic memory-related activation in schizophrenia: Meta-analysis. British Journal of Psychiatry","volume":"187","author":"Achim","year":"2005","journal-title":"Br. J. Psychiatry"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.biopsych.2008.04.011","article-title":"The Cognitive Neuroscience of Memory Function and Dysfunction in Schizophrenia","volume":"64","author":"Ranganath","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1001\/archpsyc.64.5.532","article-title":"Overlooking the obvious: A meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia","volume":"64","author":"Dickinson","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13546800344000309","article-title":"A meta-analytic review of verbal fluency deficits in schizophrenia relative to other neurocognitive deficits","volume":"10","author":"Henry","year":"2005","journal-title":"Cogn. Neuropsychiatry"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/archpsyc.1966.01730090099015","article-title":"Attention Dysfunction in Chronic Schizophrenia","volume":"14","author":"Orzack","year":"1966","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11065-005-6254-9","article-title":"A meta-analysis of cognitive deficits in adults with a diagnosis of schizophrenia","volume":"15","author":"Fioravanti","year":"2005","journal-title":"Neuropsychol. Rev."},{"key":"ref_65","first-page":"1","article-title":"A meta-analytic review of Wisconsin card sort studies in schizophrenia: General intellectual deficit in disguise?","volume":"4","author":"Laws","year":"1999","journal-title":"Psychology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1037\/0021-843X.114.4.599","article-title":"Working memory impairments in schizophrenia: A meta-analysis","volume":"114","author":"Lee","year":"2005","journal-title":"J. Abnorm. Psychol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1037\/0033-2909.133.5.833","article-title":"Neuropsychological Impairments in Schizophrenia: Integration of Performance-Based and Brain Imaging Findings","volume":"133","author":"Reichenberg","year":"2007","journal-title":"Psychol. Bull."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.biopsych.2008.03.003","article-title":"The Cognitive Neuroscience of Working Memory: Relevance to CNTRICS and Schizophrenia","volume":"64","author":"Barch","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/JCP.0000000000000691","article-title":"Aripiprazole lauroxil: Pharmacokinetic profile of this long-acting injectable antipsychotic in persons with schizophrenia","volume":"37","author":"Hard","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"St\u0119pnicki, P., Kondej, M., and Kaczor, A.A. (2018). Current concepts and treatments of schizophrenia. Molecules, 23.","DOI":"10.3390\/molecules23082087"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/mp.2012.47","article-title":"Pharmacological treatment of schizophrenia: A critical review of the pharmacology and clinical effects of current and future therapeutic agents","volume":"17","author":"Miyamoto","year":"2012","journal-title":"Mol. Psychiatry"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Komatsu, H., Fukuchi, M., and Habata, Y. (2019). Potential utility of biased GPCR signaling for treatment of psychiatric disorders. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20133207"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1152\/physrev.1998.78.1.189","article-title":"Dopamine receptors: From structure to function","volume":"78","author":"Missale","year":"1998","journal-title":"Physiol. Rev."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","article-title":"Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29,823 patients with schizophrenia","volume":"74","author":"Tiihonen","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs","volume":"10","author":"Miyamoto","year":"2005","journal-title":"Mol. Psychiatry"},{"key":"ref_76","first-page":"807","article-title":"Pharmaceutical Approval Update","volume":"40","author":"Fellner","year":"2015","journal-title":"Pharm. Ther."},{"key":"ref_77","unstructured":"Federal Drug Administration (1998). Aristada Drug Insert."},{"key":"ref_78","unstructured":"Federal Drug Administration (2002). Abilify Drug Insert Interactions."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s13318-018-0488-4","article-title":"Population Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole Lauroxil","volume":"43","author":"Hard","year":"2018","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_80","first-page":"40","article-title":"Aripiprazole Lauroxil (Aristada): Long-Acting Atypical Antipsychotic Injection Approved for the Treatment of Patients with Schizophrenia","volume":"9","author":"Raedler","year":"2016","journal-title":"Am. Health Drug Benefits"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.rinphs.2014.04.002","article-title":"Biological conversion ofaripiprazole lauroxil\u2014An N-acyloxymethyl aripiprazole prodrug","volume":"4","author":"Rohde","year":"2014","journal-title":"Results Pharma Sci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"18488","DOI":"10.1073\/pnas.1104807108","article-title":"Discovery of \u03b2-arrestin-biased dopamine D 2 ligands for probing signal transduction pathways essential for antipsychotic efficacy","volume":"108","author":"Allen","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_83","first-page":"556","article-title":"Aripiprazole lauroxil (Aristada): An extended-release, long-acting injection for the treatment of schizophrenia","volume":"41","author":"Cruz","year":"2016","journal-title":"Pharm. Ther."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40263-017-0447-7","article-title":"Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model","volume":"31","author":"Hard","year":"2017","journal-title":"CNS Drugs"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.schres.2014.09.021","article-title":"Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia","volume":"159","author":"Turncliff","year":"2014","journal-title":"Schizophr. Res."},{"key":"ref_86","first-page":"7","article-title":"Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study","volume":"31","author":"Weiden","year":"2020","journal-title":"CNS Drugs."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"085","DOI":"10.4088\/JCP.14m09741","article-title":"A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia","volume":"76","author":"Meltzer","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"ref_88","first-page":"35","article-title":"Metabolic and endocrine profiles during 1-year treatment of outpatients with schizophrenia with aripiprazole lauroxil","volume":"47","author":"Nasrallah","year":"2017","journal-title":"Psychopharmacol. Bull."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.schres.2019.01.038","article-title":"Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: A 6-month, prospective, open-label study","volume":"208","author":"Miller","year":"2019","journal-title":"Schizophr. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.schres.2017.03.003","article-title":"Efficacy and safety of aripiprazole lauroxil in schizophrenic patients presenting with severe psychotic symptoms during an acute exacerbation","volume":"190","author":"Potkin","year":"2017","journal-title":"Schizophr. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.schres.2016.09.034","article-title":"Effect of patient age on treatment response in a study of the acute exacerbation of psychosis in schizophrenia","volume":"179","author":"Targum","year":"2017","journal-title":"Schizophr. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.psychres.2019.02.021","article-title":"Social and functional outcomes with two doses of aripiprazole lauroxil vs placebo in patients with schizophrenia: A post-hoc analysis of a 12-week phase 3 efficacy study","volume":"274","author":"Correll","year":"2019","journal-title":"Psychiatry Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.2147\/NDT.S207910","article-title":"Assessing effectiveness of aripiprazole lauroxil vs placebo for the treatment of schizophrenia using number needed to treat and number needed to harm","volume":"15","author":"Citrome","year":"2019","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.4088\/JCP.15m10467","article-title":"Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles and Related Safety Considerations Among Patients With Acute Schizophrenia","volume":"77","author":"Nasrallah","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/YIC.0000000000000106","article-title":"Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia","volume":"31","author":"Citrome","year":"2016","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.4088\/JCP.17m11625","article-title":"Durability of Therapeutic Response With Long-Term Aripiprazole Lauroxil Treatment Following Successful Resolution of an Acute Episode of Schizophrenia","volume":"78","author":"McEvoy","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11920-019-1114-0","article-title":"Long-Acting Injections in Schizophrenia: A 3-Year Update on Randomized Controlled Trials Published January 2016\u2013March 2019","volume":"21","author":"Peters","year":"2019","journal-title":"Curr. Psychiatry Rep."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jval.2017.03.010","article-title":"Aripiprazole Lauroxil Compared with Paliperidone Palmitate in Patients with Schizophrenia: An Indirect Treatment Comparison","volume":"20","author":"Cameron","year":"2017","journal-title":"Value Health"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2147\/NDT.S133433","article-title":"Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole","volume":"13","author":"Salzman","year":"2017","journal-title":"Neuropsychiatr. Dis. Treat."}],"container-title":["Neurology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2035-8377\/13\/3\/29\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:24:30Z","timestamp":1760163870000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2035-8377\/13\/3\/29"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":99,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["neurolint13030029"],"URL":"https:\/\/doi.org\/10.3390\/neurolint13030029","relation":{},"ISSN":["2035-8377"],"issn-type":[{"value":"2035-8377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,1]]}}}